Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $48.0 million.

  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) rose 5.30% to $50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year increase of 5.30%. This contributed to the annual value of $48.0 million for FY2024, which is 2.98% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $48.0 million for FY2024, which was up 2.98% from $46.6 million recorded in FY2023.
  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $48.0 million during FY2024, with a 5-year trough of $25.7 million in FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $43.8 million, with a median of $46.6 million in 2023.
  • Data for Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY rose of 26.43% (in 2023) over the last 5 years.
  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $25.7 million in 2020, then grew by 19.14% to $30.6 million in 2021, then grew by 20.34% to $36.9 million in 2022, then rose by 26.43% to $46.6 million in 2023, then climbed by 2.98% to $48.0 million in 2024.